	US 12,139,512 B2
	Pre-fusion RSV F antigens
Kurt Swanson, Newton, MA (US); and Andrea Carfi, Cambridge, MA (US)
Assigned to GLAXOSMITHKLINE BIOLOGICALS SA, Rixensart (BE)
Filed by GLAXOSMITHKLINE BIOLOGICALS SA, Rixensart (BE)
Filed on Jun. 23, 2022, as Appl. No. 17/848,230.
Application 17/848,230 is a continuation of application No. 17/314,649, filed on May 7, 2021, abandoned.
Application 17/314,649 is a continuation of application No. 15/789,074, filed on Oct. 20, 2017, abandoned.
Application 15/789,074 is a continuation of application No. 14/117,588, abandoned, previously published as PCT/US2012/037773, filed on May 14, 2012.
Claims priority of provisional application 61/486,005, filed on May 13, 2011.
Prior Publication US 2022/0332766 A1, Oct. 20, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 14/005 (2006.01); A61K 39/12 (2006.01); A61K 39/155 (2006.01); A61K 39/00 (2006.01)

CPC C07K 14/005 (2013.01) [A61K 39/12 (2013.01); A61K 39/155 (2013.01); A61K 2039/53 (2013.01); C07K 2319/735 (2013.01); C12N 2760/18522 (2013.01); C12N 2760/18534 (2013.01)]

9 Claims

1. A nucleic acid encoding a respiratory syncytial virus (RSV)-F polypeptide comprising a substitution of an amino acid residue in a helix α1 corresponding to amino acid residues 145 to 157 of SEQ ID NO: 1 or 2 for a first cysteine residue and a substitution of an amino acid residue in a heptad-repeat C (HRC) region corresponding to amino acid residues 50 to 109 of SEQ ID NO: 1 or 2 for a second cysteine residue.